Literature DB >> 11506403

Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis.

G P Comi1, F Fortunato, S Lucchiari, A Bordoni, A Prelle, S Jann, A Keller, P Ciscato, S Galbiati, L Chiveri, Y Torrente, G Scarlato, N Bresolin.   

Abstract

A severe muscle enolase deficiency, with 5% of residual activity, was detected in a 47-year-old man affected with exercise intolerance and myalgias. No rise of serum lactate was observed with the ischemic forearm exercise. Ultrastructural analysis showed focal sarcoplasmic accumulation of glycogen beta particles. The enzyme enolase catalyzes the interconversion of 2-phosphoglycerate and phosphoenolpyruvate. In adult human muscle, over 90% of enolase activity is accounted for by the beta-enolase subunit, the protein product of the ENO3 gene. The beta-enolase protein was dramatically reduced in the muscle of our patient, by both immunohistochemistry and immunoblotting, while alpha-enolase was normally represented. The ENO3 gene of our patient carries two heterozygous missense mutations affecting highly conserved amino acid residues; a G467A transition changing a glycine residue at position 156 to aspartate, in close proximity to the catalytic site, and a G1121A transition changing a glycine to glutamate at position 374. These mutations were probably inherited as autosomal recessive traits since the mother was heterozygous for the G467A and a sister was heterozygous for the G1121A transition. Our data suggest that ENO3 mutations result in decreased stability of mutant beta-enolase. Muscle beta-enolase deficiency should be considered in the differential diagnosis of metabolic myopathies due to inherited defects of distal glycolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506403     DOI: 10.1002/ana.1095

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

Review 1.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  Changing a limb muscle growth program into a resorption program.

Authors:  Liquan Cai; Biswajit Das; Donald D Brown
Journal:  Dev Biol       Date:  2006-12-19       Impact factor: 3.582

Review 3.  Genomics and genetics in the biology of adaptation to exercise.

Authors:  Claude Bouchard; Tuomo Rankinen; James A Timmons
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

4.  Recurrent rhabdomyolysis due to muscle β-enolase deficiency: very rare or underestimated?

Authors:  Olimpia Musumeci; Stefen Brady; Carmelo Rodolico; Annamaria Ciranni; Federica Montagnese; M'hammed Aguennouz; Richard Kirk; Elizabeth Allen; Richard Godfrey; Sara Romeo; Elaine Murphy; Shamima Rahman; Ros Quinlivan; Antonio Toscano
Journal:  J Neurol       Date:  2014-09-30       Impact factor: 4.849

Review 5.  Glycogen metabolism and glycogen storage disorders.

Authors:  Shibani Kanungo; Kimberly Wells; Taylor Tribett; Areeg El-Gharbawy
Journal:  Ann Transl Med       Date:  2018-12

Review 6.  Neuromuscular disorders of glycogen metabolism.

Authors:  Elisabetta Gazzerro; Antoni L Andreu; Claudio Bruno
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

7.  Identification of exercise capacity QTL using association mapping in inbred mice.

Authors:  Sean M Courtney; Michael P Massett
Journal:  Physiol Genomics       Date:  2012-08-21       Impact factor: 3.107

Review 8.  Skeletal muscle disorders of glycogenolysis and glycolysis.

Authors:  Richard Godfrey; Ros Quinlivan
Journal:  Nat Rev Neurol       Date:  2016-05-27       Impact factor: 42.937

Review 9.  Inborn errors of energy metabolism associated with myopathies.

Authors:  Anibh M Das; Ulrike Steuerwald; Sabine Illsinger
Journal:  J Biomed Biotechnol       Date:  2010-05-26

10.  Nutrigenomic analysis of diet-gene interactions on functional supplements for weight management.

Authors:  Francis C Lau; Manashi Bagchi; Chandan Sen; Sashwati Roy; Debasis Bagchi
Journal:  Curr Genomics       Date:  2008-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.